For questions about Gamifant or the ordering process, connect with a Sobi Health Systems Director today.

Contact Sobi Now
Indication

Gamifant® (emapalumab-lzsg) is an interferon gamma (IFNγ)–blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary... hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

Important Safety Information
Infections

Before initiating Gamifant, patients should be evaluated for infection, including latent tuberculosis (TB)... Prophylaxis for TB should be administered to patients who are at risk for TB or known to have a positive purified protein derivative (PPD) test result or positive IFNγ release assay.

Indication

Gamifant® (emapalumab-lzsg) is an interferon gamma (IFNγ)–blocking antibody indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or intolerance with conventional HLH therapy.

Important Safety Information

Infections

Before initiating Gamifant, patients should be evaluated for infection, including latent tuberculosis (TB). Prophylaxis for TB should be administered to patients who are at risk for TB or known to have a positive purified protein derivative (PPD) test result or positive IFNγ release assay.

During Gamifant treatment, patients should be monitored for TB, adenovirus, Epstein-Barr virus (EBV), and cytomegalovirus (CMV) every 2 weeks and as clinically indicated.

Patients should be administered prophylaxis for herpes zoster, Pneumocystis jirovecii, and fungal infections prior to Gamifant administration.

Increased Risk of Infection With Use of Live Vaccines

Do not administer live or live attenuated vaccines to patients receiving Gamifant and for at least 4 weeks after the last dose of Gamifant. The safety of immunization with live vaccines during or following Gamifant therapy has not been studied.

Infusion-Related Reactions

Infusion-related reactions, including drug eruption, pyrexia, rash, erythema, and hyperhidrosis, were reported with Gamifant treatment in 27% of patients. In one-third of these patients, the infusion-related reaction occurred during the first infusion.

Adverse Reactions

In the pivotal trial, the most commonly reported adverse reactions (≥10%) for Gamifant included infection (56%), hypertension (41%), infusion-related reactions (27%), pyrexia (24%), hypokalemia (15%), constipation (15%), rash (12%), abdominal pain (12%), CMV infection (12%), diarrhea (12%), lymphocytosis (12%), cough (12%), irritability (12%), tachycardia (12%), and tachypnea (12%).

Additional selected adverse reactions (all grades) that were reported in less than 10% of patients treated with Gamifant included vomiting, acute kidney injury, asthenia, bradycardia, dyspnea, gastrointestinal hemorrhage, epistaxis, and peripheral edema.

Click here for full Prescribing Information for Gamifant.

You may also contact Sobi at medinfo.us@sobi.com or 866-773-5274.

References

  1. De Benedetti F, Prencipe G, Bracaglia C, Marasco E, Grom AA. Targeting interferon-γ in hyperinflammation: opportunities and challenges. Nat Rev Rheumatol. 2021;17(11):678-691. doi:10.1038/s41584-021-00694-z
  2. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041-4052. doi:10.1182/blood-2011-03-278127
  3. HLH diagnosis strategy. Cincinnati Children’s Hospital. Accessed March 29, 2024. https://www.cincinnatichildrens.org/service/h/hlh/clinical/test
  4. Gurunathan A, Boucher AA, Mark M, et al. Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2018;65(12):e27400. doi:10.1002/pbc.27400
  5. Chinn IK, Eckstein OS, Peckham-Gregory EC, et al. Genetic and mechanistic diversity in pediatric hemophagocytic lymphohistiocytosis. Blood. 2018;132(1):89-100. doi:10.1182/blood-2017-11-814244
  6. Cincinnati Children’s. From the Clinical Laboratories of the Cancer & Blood Diseases Institute. CXCL9. Published Winter 2019
  7. Data on file. Stockholm, Sweden: Swedish Orphan Biovitrum AB. 2018.
  8. Sepulveda FE, de Saint Basile G. Hemophagocytic syndrome: primary forms and predisposing conditions. Curr Opin Immunol. 2017;49:20-26. doi:10.1016/j.coi.2017.08.004
  9. Gamifant (emapalumab-lszg) prescribing information. Stockholm, Sweden: Sobi, Inc. 2022.

Flow cytometry testing

IconDecreased levels of the following can help identify a genetic cause3

Perforin/granzyme B
Degranulation (CD107a) or T-cell degranulation
SLAM-associated protein (SAP) (for males)
XIAP protein (for males)

CD=cluster of differentiation; SLAM=signaling lymphocytic activation molecule; XIAP=X-linked inhibitor of apoptosis protein.

Icon Flow cytometry for perforin expression and CD107a have high specificity for identifying primary HLH3

Ancillary testing3

Quantitative viral PCRs:
EBV, CMV, adenovirus, HSV 1, HSV 2, etc

CT of chest, abdomen, and neck

Testing for tick- or mosquito-borne diseases

PET-CT
followed by lymph node biopsy to evaluate for lymphoma

MRI of brain

Lyme disease

CMV=cytomegalovirus; CT=computed tomography; EBV=Epstein-Barr virus; HSV=herpes simplex virus;
MRI=magnetic resonance imaging; PCR=polymerase chain reaction; PET=positron emission tomography.

Icon These tests can help eliminate other conditions and/or define treatable underlying triggers for HLH2-5

CXCL9

Chemokine (C-X-C motif) ligand 9 (CXCL9) is a type of cytokine released almost exclusively by interferon gamma (IFNγ)-activated macrophages. The primary function of CXCL9 is to attract T cells into inflamed tissues.6

Green CXCL9 molecule Green CXCL9 molecule
Graphical steps of CXCL9 production triggered by IFNγ activity Graphical steps of CXCL9 production triggered by IFNγ activity

CXCL9 production is induced predominantly by IFNγ. Evidence suggests CXCL9 is a potential biomarker for IFNγ activity.1

CXCL9 testing sites

There is growing recognition of testing for CXCL9 as a biomarker for IFNγ activity.1,6 The following organizations offer CXCL9 testing to help with identifying primary HLH:

Machaon Diagnostics
Website www.machaondiagnostics.com/test/cxcl9-level
Turnaround time STAT: <24 hours
Routine: <1 week
Lab hours 24/7
Phone 1-800-566-3462
510-839-5600
Fax 510-839-6153
Cincinnati Children’s Hospital
Website www.testmenu.com/cincinnatichildrens/Tests/723501
Turnaround time 4 days
Lab hours Mon-Fri, 8:00 AM to 5:00 PM (ET)
Phone 513-636-4685
Fax 513-636-3861

This is not an exhaustive list of labs offering CXCL9 testing. Please check for the availability of this test within your own institution prior to contacting these sites.

Other Tests3

  • Complete blood counts
  • Ferritin
  • ALT, bilirubin
  • IL-18
  • Fibrinogen/coagulation tests
  • Triglycerides (fasting)
  • sCD25

ALT=alanine transaminase; IL-18=interleukin-18; sCD25=soluble CD25.

In the absence of an underlying cause, such as malignancy, these tests can be useful for identifying the typical features of primary HLH.3

CXCL9 reduction

Gamifant was shown to neutralize IFNγ as measured by reductions in the plasma concentration of CXCL9.7

View the data

Download CXCL9 testing brochure